Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04078178 · ClinicalTrials.gov registry record · NA
Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment
A NA study, sponsored by Steven E Arnold, MD.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT04078178 is a NA study that has completed, run by Steven E Arnold, MD. The registered enrollment target is 61 participants.
The verdict
NCT04078178, a NA study, has completed, sponsored by Steven E Arnold, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
In this research study we want to learn more about whether taking Niagen, a daily supplement containing a form of Vitamin B3, will improve cognitive function, mood, and daily activity in people with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI).
Interventions
- DIETARY_SUPPLEMENT Placebo Comparator
- DIETARY_SUPPLEMENT Niagen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2022-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04078178
The ClinicalTrials.gov registry entry for NCT04078178 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steven E Arnold, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT04078178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04078178 about?
NCT04078178 is a clinical study titled "Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment". In this research study we want to learn more about whether taking Niagen, a daily supplement containing a form of Vitamin B3, will improve cognitive function, mood, and daily activity in people with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI).
What is the current status of trial NCT04078178?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2020-10-30. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT04078178?
The interventions under investigation include: Placebo Comparator (DIETARY_SUPPLEMENT), Niagen (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04078178?
This trial is sponsored by Steven E Arnold, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.